易瑞沙与放疗同期治疗非小细胞肺癌脑转移的临床效果分析

目的探讨易瑞沙与放疗同期治疗非小细胞肺癌脑转移的临床效果。方法选取非小细胞肺癌脑转移患者78例,将患者随机分为联合组及常规组。所有患者均接受全脑放疗及局部转移灶放疗。联合组在放疗基础上服用易瑞沙250 mg,1次/d,持续8周以上。比较2组的治疗效果及不良反应。结果联合组患者的PR、RR及DCR均显著高于常规组,而PD显著低于常规组(P0.05);联合组中,EGFR突变阳性患者有效率为91.30%,显著高于EGFR突变阴性的62.50%(P0.05)。联合组治疗后KPS评分、中位生存时间及生存率均显著优于常规组(P0.05);联合组痤疮样皮疹的发生率显著高于常规组(P0.05)。结论易瑞沙联合放疗能够提高NSCLC脑转移患者的临床疗效、生活质量及生存期。

Clinical efficacy of iressa combined with radiotherapy in treatment of patients with non-small cell lung cancer and brain metastasis

Objective To explore the clinical efficacy of iressa combined with radiotherapy in treatment of patients with non-small cell lung cancer (NSCLC) and brain metastasis.Methods Totally 78 NSCLC patients with brain metastasis were selected and divided into combined group and conventional group.All the patients received whole brain radiotherapy and radiotherapy for local metastasis.The combined group was additionally treated with iressa 250 mg/d, one time per day, and this treatment lasted for more than 8 weeks.Effect and complications were compared between two groups.Results The PR rate, effective rate and disease control rate in the combined group were significantly higher than those in the conventional group, while the disease progression rate was significantly lower than the conventional group (P<0.05).In the combined group, the positive rate of EGFR mutation was 91.30%, which was significantly higher than 62.50% of the negative rate of EGFR mutation (P<0.05).The KPS score, mean survival time and survival rate after treatment in the combined group were significantly better than those in the conventional group (P<0.05).Conclusion Iressa combined with radiotherapy can effectively improve the clinical effect, the survival time and the quality of life in NSCLC patients with brain metastasis.